Treatment flow
2022-02-05 15:18:00 15 举报AI智能生成
BC treatment flow
作者其他创作
大纲/内容
<b><font color="#e57373">Her2+ BC</font></b>
<b><i><font color="#f44336">Neo adjuvant</font></i></b>
I: TCbHP, THP
II: TCbH, AC-THP, clinical trials
<b><i><font color="#f44336">adjuvant</font></i></b>
<b>neo adj. pCR</b>
if H in neo adjuvant
I: H
II: HP
if HP in neo adjuvant
I: HP
II: H
<b>neo adj.Non-pCR</b>
if H in neo adjuvant
I: T-DM1, HP
II: H
if HP in neo adjuvant
I: T-DM1, HP
<b>lymph nodes+</b>
I: AC+THP, TCbHP
II: AC-TH, TCbH
III: H-Neratinib
<b>lymph nodes- <br>high risk(T>2cm) etc.</b>
I: AC-TH,TCbH
II: AC-THP,TCbHP
III: H-Neratinib
<b>lymph nodes-<br>T≤2cm</b>
I: TC+H
II: wTH
III: chemo-H
<b>HR+ no chemo</b>
II: H+endocrine
<b><i><font color="#f44336">mBC</font></i></b>
<b>no H before/ qulified to H again</b>
I: THP, TXH
II: H+chemo, pyrotinib+capecitabine
III: H+P+chemo
<b>fail to H</b>
I: pyrotinib+capecitabine
II: T-DM1, lapatinib+capecitabine
III: Neratinib+capecitabine, pyrotinib, TKI+Chemo, H+Chemo
<b><i><font color="#f44336">TNBC</font></i></b>
<b><i><font color="#f44336">Neo adjuvant</font></i></b>
I: TAC, AT, TP
II: AC-T, clinical trials: T+PD-(L)1
<b><i><font color="#f44336">adjuvant</font></i></b>
<b>lymph nodes+<br>/T>2cm</b>
I: AC-T, ddAC-ddT
II: TAC, FEC-T,chemo-capecitabine
III: FAC*6
<b>lymph nodes- <br>and T≤2cm</b>
I: AC, TC
II: AC-T
<b><i><font color="#f44336">mTNBC</font></i></b>
<b>failed to A treatment</b>
I: T single: nab-paclitaxel, docetaxel，paclitaxel<br>combo: TX, GP, GT, TP
II: single: X, N, G, Etoposide<br>combo: nab-paclitaxel +PD-(L)1;T+Beva
III: paclitaxel liposomes, Olaparib, Doxorubicin liposomes, chemo+PD-1
<b>failed to A and T treatment</b>
I: single: X, N, G<br>combo: NP, GP, NX
II: single: Eribulin, nab-paclitaxel, Etoposide<br>combo: Utidelone+X, X+beva, nab-paclitaxel+chemo
III: paclitaxel liposomes, Doxorubicin liposomes,
<b><i><font color="#f44336">HR+</font></i></b>
<b><i><font color="#f44336">neo adjuvant</font></i></b>
I: TAC, AT
II: AC-T
if not suitable for chemo
<b>postmenopausal</b>
I: AI
II: AI+CDK4/6i,Fulvestrant
<b>pre-menopausal</b>
II: OFS+AI, OFS+AI+CDK4/6i
<i><b><font color="#f44336">adjuvant</font></b></i>
<b>Chemo</b>
<b>high risk: 1, lymph nodes≥4+<br>2, lymph nodes 1-3 with other risk fators</b>
I: AC-T,ddAC-ddT
II: TAC, FEC-T
III: FAC*6
<b>low risk: 1, lymph nodes1-3+; 2, Ki-67 high (≥30%）<br>3, T>2cm; 4, age<35 yo</b>
I: AC, TC
II: AC-T
<b>Endocrine therapy</b>
<b>postmenopausal</b>
I: AI: 5 years, TAM then AI 5 years
II: TAM 2-3 years -- AI 2-3 years
III: TAM 5 years
intensive therapy if high risk<br>1, lymph node+; 2, G3; 3, other high risk fators
I: AI
II: switch to TAM
<b>pre-menopausal</b>
low rish(all): 1, lymph nodes-; 2, G1; 3, T≤2cm; 4, low Ki-67
TAM 5 years
meet one of: 1, G2 or G3; 2, lymph nodes 1-3; 3, T>2cm
I: OFS+TAM years
II: OFS+ AI 5 years
III: TAM
lymph nodes≥ 4
I: OFS+AI 5 years
II: OFS+TAM 5 years
III: TAM
<b><i><font color="#f44336">mBC</font></i></b>
<b>no endocrine before</b>
I: AI+CDK4/6i, Fulvestrant
II: AI, Fulvestrant+CDK4/6i
III: TAM
<b>TAM failed </b>
I:AI+CDK4/6i, AI+Chidamide, Fulvestrant+CDK4/6i
II: AI, Fulvantrant
<b>NSAIDs AI failed</b>
I: SAI+Chidamide, Fulvestrant+Abemaciclib, Fulvestrant+Palbociclib
II: SAI+CDK4/6i, Fulvestrant, SAI+Everolimus
III: SAI, TAM, Toremifene，Progestogen
<b>SAIDs AI falied</b>
I: Fulvestrant+Abemaciclib, Fulvestrant+Palbociclib
II: Fulvestrant, NSAI + CDK4/6i
III: NSAIDs, TAM or Roremifene, Progestogen
收藏
0 条评论
下一页
